In the Netherlands, a collaboration of (pediatric) nephrologists nationwide led to a new treatment guideline which in the end enables tailored therapy with the orphan drug eculizumab and a considerable cost reduction. The nationwide study CUREiHUS, initiated by the Radboudumc and led by Dr Nicole van de Kar, pediatric nephrologist, Prof Jack Wetzels, nephrologist and Kioa Wijnsma, PhD candidate, is one of the hallmarks of this new national approach and acquires a lot of (inter)national attention.Eculizumab, nowadays the standard treatment for patients with atypical hemolytic uremic syndrome (aHUS), is considered one of world’s most expensive drugs with costs as high as €500,000 per patient per year. Besides the high price tag of eculizumab, physicians treating aHUS patients have sincere concerns regarding the long term consequences, when eculizumab is used as lifelong maintenance therapy. Especially since there is little to no evidence to support this life long duration. In the Netherlands, this led to the development of a new Dutch guideline, drafted by the National Working Group aHUS, which enables a restrictive eculizumab regimen. The implementation of this guideline led to a whole new political discussion in the Netherlands. Only recently, the National Health Care Institute of the Netherlands declined reimbursement of eculizumab as lifelong therapy. However, with the implementation of this new guideline, which is shown to be (cost) effective and safe, the minister of Health has decided to reimburse eculizumab reimbursed, solely when subscribed according to the new guideline. Instead of lifelong maintenance therapy with the orphan drug eculizumab, patients will receive eculizumab for three months after which therapy will be evaluated and while closely monitored withdrawn if possible. With this nationwide prospective study, abbreviated CUREiHUS (NTR5988), sponsored by ZonMw and Zorgverzekeraars Nederland, this restrictive regimen will be monitored for and evaluated after four years.
Recently the newspaper NRC published a extensive background story regarding this new and unique phenomenon in the Netherlands, interviewing both involved patients as physicians and politicians.
See also: link.
Related news items
Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute30 June 2020
Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.read more
Stefan Listl member of the new Lancet Commission on Oral Health29 June 2020
In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection29 June 2020
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more
UMD Catalist grant for Mohammad Alsady and Federica Conte24 June 2020
They received this award to explore the potential of hiPS-derived skeletal muscle cells as model to investigate muscular pathophysiologic mechanisms in phosphoglucomutase I deficiency.read more